Literature DB >> 12044958

Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects.

Kenichi Kitani1, Chiyoko Minami, Ken-ichi Isobe, Kayoko Maehara, Setsuko Kanai, Gwen O Ivy, Maria-Christina Carrillo.   

Abstract

(--)Deprenyl, a monoamine oxidase B (MAO B) inhibitor is known to upregulate activities of anti-oxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) in brain dopaminergic regions. The drug is also the sole chemical which has been repeatedly shown to increase life spans of several animal species including rats, mice, hamsters and dogs. Further, the drug was recently found to enhance anti-oxidant enzyme activities not only in brain dopaminergic regions but also in extra-brain tissues such as the heart, kidneys, adrenal glands and the spleen. We and others have also observed mobilization of many humoral factors (interferone (INF)-gamma, tumor necrosis factor (TNF)-alpha, interleukine (IL)-1beta,2,6, trophic factors, etc.) and enhancement of natural killer (NK) cell functions by (-)deprenyl administration. An apparent extension of life spans of experimental animals reported in the past may be better explained by these new observations that (-)deprenyl upregulate SOD and CAT activities not only in the brain but also in extra-brain vital organs and involve anti-tumorigenic as well as immunomodulatory effect as well. These combined drug effects may lead to the protection of the homeostatic regulations of the neuro-immuno-endocrine axis of an organism against aging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044958     DOI: 10.1016/s0047-6374(01)00392-x

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  19 in total

Review 1.  Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.

Authors:  Orit Bar-Am; Tamar Amit; Moussa B Youdim; Orly Weinreb
Journal:  J Neural Transm (Vienna)       Date:  2015-04-10       Impact factor: 3.575

Review 2.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

3.  Antiperoxidative and antiinflammatory effect of Sida cordifolia Linn. on quinolinic acid induced neurotoxicity.

Authors:  S S Swathy; Seema Panicker; R S Nithya; M M Anuja; S Rejitha; M Indira
Journal:  Neurochem Res       Date:  2010-05-25       Impact factor: 3.996

Review 4.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

5.  Bacopa monnieri and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-κB pathways in the spleen of female wistar rats.

Authors:  Hannah P Priyanka; Preetam Bala; Sindhu Ankisettipalle; Srinivasan ThyagaRajan
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

6.  L-Deprenyl reverses age-associated decline in splenic norepinephrine, interleukin-2 and interferon-γ production in old female F344 rats.

Authors:  Srinivasan Thyagarajan; Kelley S Madden; Gary W Boehm; Suzanne Y Stevens; David L Felten; Denise L Bellinger
Journal:  Neuroimmunomodulation       Date:  2012-11-29       Impact factor: 2.492

7.  Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Authors:  Orly Weinreb; Tamar Amit; Yotam Sagi; Noam Drigues; Moussa B H Youdim
Journal:  J Neural Transm (Vienna)       Date:  2009-04-25       Impact factor: 3.575

Review 8.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  What really declines with age? The Hayflick Lecture for 2006 35th American Aging Association.

Authors:  Kenichi Kitani
Journal:  Age (Dordr)       Date:  2007-01-11

10.  Antioxidant effects of selegiline in oxidative stress induced by iron neonatal treatment in rats.

Authors:  Patrícia Budni; Maria Noemia Martins de Lima; Manuela Polydoro; José Cláudio Fonseca Moreira; Nadja Schroder; Felipe Dal-Pizzol
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.